VIVE — Vivesto AB Share News
0.000.00%
Last trade - 00:00- SEK95.10m
- SEK63.62m
Brief: Vivesto Strengthens Cantrixil Program With New Preclinical Results And Patent Application
Brief: Vivesto Q3 Operating Loss Narrows To SEK 10,812 Thousand
Brief: Vivesto's Paccal Vet Receives Limited Market Classification In EU
Brief: Vivesto Enters Agreement With Zhida Pharma For Apealea
Brief: Vivesto Q2 Operating Loss Narrows To SEK 11.0 Mln
Brief: Vivesto Receives Positive Preclinical Efficacy Data For Cantrixil
Brief: Vivesto Q1 Operating Loss Narrows To SEK 9.2 Mln
Brief: Vivesto Q4 Operating Loss Narrows To SEK 64.9 Million
Brief: Vivesto's Patent Application For XR-18 Gets Approval From EPO
Brief: Vivesto Gets MUMS Designation By FDA For Drug Paccal Vet
Brief: Vivesto Makes Impairment Charge Of SEK 43.2 Million
Brief: Vivesto, Elevar Sign Agreement Ending Apealea Partnership
Brief: Vivesto Q3 Operating Profit SEK -16.565 Million
Brief: Vivesto Introduces Cost-Saving Measures, Stops Activities In Uppsala
Brief: Vivesto Focuses Its Project Portfolio And Introduces Cost-Saving Measures
Brief: Vivesto Delists From Frankfurt Stock Exchange
Brief: Vivesto Q2 Oper Loss Narrows To SEK 28.8 Mln
Brief: Vivesto Q2 EPS at SEK -0.05
Brief: Vivesto Announces Early Termination Of Patient Enrollment